An analysis of the targets companies are pursuing to retain muscle while losing fat

The CCO role is evolving, argue John Archer and Roger Longman, as applicants must challenge entrenched views and manage a growing set of stakeholders with creativity

In BioCentury’s Clinical Report, Pfizer and BMS miss out on market opportunities, and more

Plus: The week’s gainers and decliners after data

AZ’s latest data position AZD0780 as slightly less effective but more convenient than PCSK9 competition

BioCentury’s roundup of translational innovations also includes blood detection of pregnancy complications, BBB-crossing antibodies, and more

As human data are poised to deliver causal targets and more precise interventions, caving to anti-DEI rhetoric

Pharma had held minority stake in 2019 spinout of mAb, now in Phase III for atrial fibrillation and cancer-associated thrombosis

Genetic therapies compete in the same indications, as degraders come of age